A detailed history of Glenview Trust CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Glenview Trust CO holds 6,738 shares of VRTX stock, worth $2.75 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
6,738
Previous 6,750 0.18%
Holding current value
$2.75 Million
Previous $3.16 Million 0.95%
% of portfolio
0.06%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $5,520 - $6,069
-12 Reduced 0.18%
6,738 $3.13 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $70,705 - $87,395
180 Added 2.74%
6,750 $3.16 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $73,384 - $80,294
180 Added 2.82%
6,570 $2.75 Million
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $33,614 - $40,246
98 Added 1.56%
6,390 $2.6 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $17,921 - $20,058
57 Added 0.91%
6,292 $2.21 Million
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $43,900 - $50,080
-155 Reduced 2.43%
6,235 $1.96 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $150,595 - $169,419
527 Added 8.99%
6,390 $1.85 Million
Q3 2022

Nov 04, 2022

BUY
$273.83 - $305.53 $187,299 - $208,982
684 Added 13.21%
5,863 $1.7 Million
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $5,639 - $7,021
24 Added 0.47%
5,179 $1.46 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $1.14 Million - $1.35 Million
5,155 New
5,155 $1.35 Million
Q4 2021

Feb 10, 2022

SELL
$177.01 - $223.45 $688,568 - $869,220
-3,890 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $347,361 - $388,725
1,915 Added 96.96%
3,890 $705,000
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $370,292 - $436,672
1,975 New
1,975 $398,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Glenview Trust CO Portfolio

Follow Glenview Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenview Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Glenview Trust CO with notifications on news.